Fundraising Fox

Foresite Capital β€” 2018 Investments

5 investments dated 2018 Β· listed companies and verified rows first Β· show all

Fulcrum TherapeuticsinNASDAQ: FULCAug 2018

BiotechCambridge, US

Robert Gould(Executive Officer, Director)

BoardAlan Ezekowitz(Director)inMark Levin(Director)inJames Geraghty(Director)James Collins(Director)

Board seatJames TananbaumΒ· per SEC Form D

Co-investorsThird Rock Ventures

Allogene Therapeuticsallogene.comin𝕏NASDAQ: ALLOApr 2018

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.

BiotechHealthtechMedical DevicesSouth San Francisco, US

ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)

BoardOWEN WITTE(Director)

Co-investorsAvoro Capital AdvisorsTPGVida Ventures

Beam Therapeuticsbeamtx.comin𝕏NASDAQ: BEAMNov 2018

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

David R. Liu(Founder and Inventor)J. Keith Joung(Founder and Inventor)Feng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARCH Venture PartnersDreamers VCEight Roads VenturesF-Prime CapitalGV (Google Ventures)HongShan Capital Group+1 more

Theseus Pharmaceuticalstheseusrx.comJun 2018

BiotechCambridge, US

William C. Shakespeare(Director)

BoardIain Dukes(Executive Officer, Director)inCarl Gordon(Director)in

Board seatMichael RomeΒ· per SEC Form D

Co-investorsLongitude CapitalNextech InvestOrbiMed

Eidos TherapeuticsMar 2018

BiotechSan Francisco, US

NEIL KUMAR(Executive Officer, Director)JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)CHRISTINE SIU(Executive Officer)HOYOUNG HUH(Director)ERIC AGUIAR(Director)

Co-investorsRA Capital

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.